Siddeshwar Patil

Siddeshwar Patil

Auto-generated profile, based on publicly available information

Siddeshwar Patil

Pinderfields General Hospital, Yorkshire Regional Spinal Injuries Centre, Wakefield, England

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2015 in Journal of Medical Engineering & Technology
Verified
Journal Article
Closed access
PDF file
SPSiddeshwar Patil
Siddeshwar Patil
WRWajid A. Raza
Wajid A. Raza
FJFiras Jamil
Firas Jamil
RCRichard Caley
Richard Caley
RORory J. O’cOnnor
Rory J. O’cOnnor
(2015). Functional electrical stimulation for the upper limb in tetraplegic spinal cord injury: a systematic review. Journal of Medical Engineering & Technology: Vol. 39, No. 7, pp. 419-423. doi: 10.3109/03091902.2015.1088095

25 August 2022 in Turkish Journal of Physical Medicine and Rehabilitation
Verified
Journal Article
Open access
RSRajinder Singh
Rajinder Singh
BGBhajneek Grewal
Bhajneek Grewal
SPSiddeshwar Patil
Siddeshwar Patil

31 July 2026 in Journal of Natural Remedies
Verified
Journal Article
Open access
AIAkshay V. Ingle
Akshay V. Ingle
SPS. S. Patil
S. S. Patil
Background: Diabetes mellitus is a chronic metabolic disorder causing hyperglycaemia and organ damage. Limitations of current therapies highlight the need for safer, plant-based alternatives. The antidiabetic and organ-protective potential of Abelmoschus ficulneus remains largely unexplored. Aim: To evaluate the antidiabetic, hepatoprotective, and nephroprotective effects of A. ficulneus leaf extracts and fractions in streptozotocin-induced diabetic rats. Methods: Acute oral toxicity of A. ficulneus leaf extracts was assessed up to 2000 mg/kg. Diabetes was induced in Wistar rats using streptozotocin (60 mg/ kg). Animals were allocated to control, diabetic control, glimepiride-treated, extract-treated, and fraction-treated groups. Blood glucose and body weight were monitored on days 0, 7, 14, and 21. At study completion, blood and urine samples were analysed for renal (serum creatinine, serum total protein, urine total protein) and hepatic (SGPT, SGOT, serum bilirubin) biomarkers using commercial kits. Liver and kidney tissues were examined histopathologically. Results: No mortality or toxicity was observed up to 2000 mg/kg. Streptozotocin caused marked hyperglycaemia (375.17 ± 1.60 vs. 64.16 ± 2.71 mg/dL in controls) and body weight loss (−19.41 ± 0.72 g). Treatment with A. ficulneus significantly reduced blood glucose, with the aqueous extract (200 mg/kg) lowering levels to 99.5 ± 3.69 mg/dL, comparable to glimepiride (97.83 ± 1.04 mg/ dL). Weight loss was attenuated, with methanol fraction AF008-F5 (200 mg/kg) showing the greatest improvement (−0.46 ± 0.02 g). Elevated hepatic markers were significantly reduced by AF008-F5 (SGPT: 52.36 ± 0.52 IU/L, SGOT: 53.51 ± 0.21 IU/L, bilirubin: 1.01 ± 0.01 mg/dL). Histopathological findings confirmed protection against diabetes-induced liver and kidney damage. Conclusion: A. ficulneus leaf extracts, particularly the bioactive methanol fraction AF008-F5, demonstrated significant antihyperglycaemic, hepatoprotective and nephroprotective effects in diabetic rats without observable toxicity. These findings support the potential of A. ficulneus as a promising natural therapeutic candidate for diabetes and its associated complications. Major Finding: Abelmoschus ficulneus fractions significantly ameliorated streptozotocin-induced hyperglycemia and associated organ dysfunction in rats. Among the tested fractions, the methanolic fraction (AF011-F5, 200 mg/kg) exhibited the greatest efficacy by lowering blood glucose levels, improving body weight and restoring renal and hepatic biomarkers.

29 October 2020 in Spinal Cord Series and Cases
Verified
Journal Article
Closed access
PDF file
RSRajinder Singh
Rajinder Singh
BGBhajneek Grewal
Bhajneek Grewal
SPSiddeshwar Patil
Siddeshwar Patil